BR0316523A - Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente - Google Patents

Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente

Info

Publication number
BR0316523A
BR0316523A BR0316523-0A BR0316523A BR0316523A BR 0316523 A BR0316523 A BR 0316523A BR 0316523 A BR0316523 A BR 0316523A BR 0316523 A BR0316523 A BR 0316523A
Authority
BR
Brazil
Prior art keywords
peptides
patient
treating
compound
pharmaceutical composition
Prior art date
Application number
BR0316523-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Amy L Allan
Stephanie A Hopkins
Patricia L Gladstone
Graham Parry
Marian L Plunkett
Robert J Ternansky
Won Hyung Yoon
Fernando Donate
Andrew Mazar
Sean M O'hare
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of BR0316523A publication Critical patent/BR0316523A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR0316523-0A 2002-11-25 2003-11-25 Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente BR0316523A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42917402P 2002-11-25 2002-11-25
US47553903P 2003-06-02 2003-06-02
PCT/US2003/038175 WO2004047771A2 (en) 2002-11-25 2003-11-25 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR0316523A true BR0316523A (pt) 2005-10-18

Family

ID=32397181

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0316523-0A BR0316523A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0316550-7A BR0316550A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0316550-7A BR0316550A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente

Country Status (14)

Country Link
US (2) US20050020810A1 (https=)
EP (2) EP1569678A4 (https=)
JP (2) JP2006515866A (https=)
KR (2) KR20050096917A (https=)
AU (2) AU2003297609A1 (https=)
BR (2) BR0316523A (https=)
CA (2) CA2507045A1 (https=)
EA (2) EA200500870A1 (https=)
HR (2) HRP20050585A2 (https=)
MX (2) MXPA05005545A (https=)
NO (2) NO20053112L (https=)
NZ (2) NZ540363A (https=)
PL (2) PL377701A1 (https=)
WO (2) WO2004047771A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
EP1766405A1 (en) * 2004-05-21 2007-03-28 MDS Inc. doing Business Through Its MDS Pharma Services Division Method of quantifying the cell-binding properties of a medical device
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
KR20070100832A (ko) * 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
WO2006084016A1 (en) 2005-02-01 2006-08-10 Attenuon, Llc ACID ADDITION SALTS OF Ac-PHSCN-NH2
AU2006350707A1 (en) * 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
AU2016213759B2 (en) * 2006-11-08 2018-03-29 Chongxi Yu Transdermal delivery systems of peptides and related compounds
PL2427475T3 (pl) 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
KR101228668B1 (ko) 2010-09-17 2013-01-31 가톨릭대학교 산학협력단 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
CA2839702C (en) 2011-06-23 2021-04-20 Board Of Regents, The University Of Texas System Identifying peptides at the single molecule level
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
JP6206987B2 (ja) * 2012-05-11 2017-10-04 メディカス バイオサイエンシーズ，エルエルシー 網膜剥離の処置のための生体適合性ヒドロゲル製剤
AU2012381990B2 (en) 2012-06-04 2017-02-23 Nutrien Ag Solutions (Canada) Inc. Formulations containing paraffinic oil and anti-settling agent
ES2664411T3 (es) 2013-03-15 2018-04-19 Suncor Energy Inc. Composiciones herbicidas
JP5970439B2 (ja) * 2013-09-20 2016-08-17 チョンシー ユー ペプチド及び関連化合物の経皮送達システム
CA3208970A1 (en) 2014-09-15 2016-05-06 Board Of Regents, The University Of Texas System Improved single molecule peptide sequencing
CA3110800A1 (en) 2018-07-12 2020-01-16 Board Of Regents, The University Of Texas System Molecular neighborhood detection by oligonucleotides
CA3117476A1 (en) 2018-10-05 2020-04-09 Board Of Regents, The University Of Texas System Solid-phase n-terminal peptide capture and release
WO2020150831A1 (en) 2019-01-25 2020-07-30 Suncor Energy Inc. Photosensitizer compounds, methods of manufacture and application to plants
CN113677204B (zh) 2019-02-15 2024-03-05 桑科能源股份有限公司 原卟啉ix衍生物改善植物健康的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
WO1981003330A1 (fr) 1980-05-13 1981-11-26 Mitsubishi Chem Ind Derives de la cysteine et leur production
US4394519A (en) * 1982-01-19 1983-07-19 Research Corporation Amino acid blocking agents
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
EP0814860B1 (en) 1995-03-14 1999-11-03 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US5970974A (en) * 1995-03-14 1999-10-26 Siemens Aktiengesellschaft Dosating unit for an ultrasonic atomizer device
US5618513A (en) 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
CA2265484C (en) * 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6331409B1 (en) * 1996-11-21 2001-12-18 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6001965A (en) * 1996-11-21 1999-12-14 The Regents Of The University Of Michigan Anticancer compounds and methods
US6011170A (en) * 1997-01-14 2000-01-04 Kaneka Corporation Process for producing of cysteine derivatives
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
JP2001516055A (ja) * 1997-09-10 2001-09-25 ザ バーナム インスティチュート 腫瘍中の血管形成血管系にホーミングする分子を同定する方法
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
JP2002525265A (ja) 1998-08-14 2002-08-13 アドミニストレイターズ オブ ザ トゥレーン エジュケーショナル ファウンド 成長ホルモン放出活性を有する化合物
ATE366936T1 (de) 2001-01-18 2007-08-15 Univ Michigan Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.

Also Published As

Publication number Publication date
US20050020810A1 (en) 2005-01-27
NZ540889A (en) 2008-09-26
CA2506813A1 (en) 2004-07-29
JP2006514116A (ja) 2006-04-27
HRP20050584A2 (hr) 2006-04-30
MXPA05005469A (es) 2005-09-08
EP1569678A4 (en) 2008-01-02
EA200500870A1 (ru) 2006-04-28
MXPA05005545A (es) 2005-10-18
JP2006515866A (ja) 2006-06-08
PL377763A1 (pl) 2006-02-20
PL377701A1 (pl) 2006-02-06
HRP20050585A2 (en) 2006-02-28
WO2004063213A3 (en) 2005-03-03
KR20050096917A (ko) 2005-10-06
NO20053111L (no) 2005-08-24
EA200500871A1 (ru) 2006-04-28
WO2004047771A2 (en) 2004-06-10
WO2004063213A2 (en) 2004-07-29
EP1594521A2 (en) 2005-11-16
NZ540363A (en) 2007-11-30
WO2004047771A3 (en) 2005-09-15
CA2507045A1 (en) 2004-06-10
NO20053112L (no) 2005-08-05
EP1594521A4 (en) 2008-01-09
KR20050097494A (ko) 2005-10-07
US7517855B2 (en) 2009-04-14
NO20053112D0 (no) 2005-06-24
AU2003298726A1 (en) 2004-08-10
BR0316550A (pt) 2005-10-04
NO20053111D0 (no) 2005-06-24
US20040162239A1 (en) 2004-08-19
AU2003297609A1 (en) 2004-06-18
EP1569678A2 (en) 2005-09-07

Similar Documents

Publication Publication Date Title
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
UY26130A1 (es) Compuestos para tratar la obesidad
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
DE60329756D1 (de) Mitotische kinesin-hemmer
DE60329990D1 (de) Mitotische kinesin-hemmer
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
BR0310092A (pt) Combinação de compostos orgânicos
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
BRPI0414386A (pt) composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
BRPI0409865A (pt) injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.